 7. Any severe or unstable concomitant condition or disease e.g., known significant neurological deficit, cancer, hematological, or coronary disease, or chronic condition e.g., psychiatric disorder which, in the opinion of the Investigator, would affect the assessment of the safety or efficacy of the study drug 